CD59 Human shRNA Lentiviral Particle (Locus ID 966)

CAT#: TL316484V

CD59 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL316484A virus into HEK293 cells. TL316484A virus was prepared using lenti-shRNA TL316484A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL316484B virus into HEK293 cells. TL316484B virus was prepared using lenti-shRNA TL316484B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL316484C] virus into HEK293 cells. [TL316484C] virus was prepared using lenti-shRNA [TL316484C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL316484D] virus into HEK293 cells. [TL316484D] virus was prepared using lenti-shRNA [TL316484D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 966
• Synonyms: 1F5; 16.3A5; EJ16; EJ30; EL32; G344; HRF-20; HRF20; MAC-IP; MACIF; MEM43; MIC11; MIN1; MIN2; MIN3; MIRL; MSK21; p18-20
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_000611, NM_001127223, NM_001127225, NM_001127226, NM_001127227, NM_203329, NM_203330, NM_203331, NM_203329.1, NM_203329.2, NM_203331.1, NM_203331.2, NM_000611.1, NM_000611.2, NM_000611.3, NM_000611.4, NM_000611.5, NM_203330.1, NM_203330.2, NM_001127223.1, NM_001127227.1, NM_001127225.1, NM_001127226.1, BC001506, BC001506.2, BC033226, BM457931, BM551313, BM680161, BM724931, BM829941, BM911556, NM_000611.6
• UniProt ID: P13987
• Summary: This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations in this gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified for this gene. [provided by RefSeq, Jul 2008]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).